| Literature DB >> 29928446 |
Liang Sun1, Yizhou Yao1, Guofeng Pan1, Shenghua Zhan2, Weiqiang Shi2, Ting Lu3, Jinfeng Yuan1, Kangjun Tian1, Linhua Jiang1, Shiduo Song1, Xinguo Zhu1, Songbing He1.
Abstract
Fatty acid synthase (FASN), the main enzyme involved in de novo lipogenesis, is overexpressed in several types of tumor tissues. In addition, it is associated with tumor cell proliferation, metastasis, epithelial-mesenchymal transition (EMT) and a poor prognosis. However, the precise functions and internal mechanisms of FASN with regard to the proliferation, metastasis and EMT in gastric cancer (GC) cells remain elusive. The present study investigated FASN protein expression in 18 randomly selected pairs of GC tumors and matched normal tissues by western blot analysis. FASN-specific small interfering RNA (siRNA) was then transfected into SGC-7901 cells to examine the effect of FASN on proliferation and migration in vitro. Western blotting was used to detect the protein expression of FASN, EMT-related markers and key signaling molecules of the mechanistic target of rapamycin/zinc finger protein GLI1 (mTOR/Gli1) pathway. Reverse transcription-quantitative polymerase chain reaction was conducted to detect the mRNA expression of FASN and EMT-related markers. The FASN level was higher in the GC tissues compared with that in the surrounding normal tissues. Knockdown of FASN suppressed GC cell proliferation and metastasis in vitro. The silencing of FASN expression using siRNA reversed EMT at the protein and mRNA levels and decreased the expression of Gli1 via regulation of AMP-activated protein kinase/mTOR and protein kinase B/mTOR signaling in GC cells. Inhibition of FASN suppresses GC proliferation and metastasis through targeting of the mTOR/Gli1 signaling pathway, indicating that it may serve as a potential target for the treatment of GC.Entities:
Keywords: epithelial-mesenchymal transition; fatty acid synthase; gastric cancer; metastasis
Year: 2018 PMID: 29928446 PMCID: PMC6006441 DOI: 10.3892/ol.2018.8648
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967